Ergotrics SA
The score of Ergotrics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -64 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Ergotrics's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −63,582 € | ||||
| Equity | −325,955 € | ||||
| Cash | 67,265 € | ||||
| EBITDA | 30,886 € | ||||
| Total assets | 376,384 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 01 Jul 2026
- Year ended 31 Dec 2024filed on 03 Jul 2025
- Year ended 31 Dec 2023filed on 04 Jul 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
- Year ended 31 Dec 2021filed on 22 Jul 2022
Ergotrics's financial analysis
- Solvency-86.6%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Ergotrics
Ergotrics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0506.642.480
- VAT number
- BE0506642480
- Peppol
- Registered · 0208:0506642480 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 08 Dec 2014
- Registered office
- 2300 Turnhout
- Latest accounts
- 2025 · filed on 01 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Ergotrics (SA) has been based in Turnhout since 2014, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 63,582 € and equity of −325,955 €; its revenue is not published. Its solvency stands at -86.6%, below the median of its sector (60.4%).
Companies similar to Ergotrics
Companies in the same business, of comparable size and area, outside its group.
- Mentana DX Research and experimental development on natural sciences and engineering Evergem · balance sheet 229,998 €
- Orineo Research and experimental development on natural sciences and engineering Kortenberg · balance sheet 394,122 €
- Grand Medical (Europe) Research and experimental development on natural sciences and engineering Niel · balance sheet 135,260 €
- CTTec Research and experimental development on natural sciences and engineering Menen · balance sheet 259,750 €
- MDTrials Research and experimental development on natural sciences and engineering Bruges · balance sheet 372,427 €
- Pharmacosmedics Research and experimental development on natural sciences and engineering Knokke-Heist · balance sheet 289,301 €
- Flindr Labs Manufacture of pharmaceutical preparations Ghent · balance sheet 262,929 €
- Blue Armor Research and experimental development on natural sciences and engineering Neupré · balance sheet 489,312 €
Frequently asked questions about Ergotrics
What is the revenue of Ergotrics?
Ergotrics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Ergotrics?
In Belgium, the VAT number is the company number prefixed with BE: BE0506642480 for Ergotrics, if the company is VAT-registered. Its company number (CBE) is 0506.642.480.
Where is the registered office of Ergotrics?
According to the CBE register, the registered office of Ergotrics is in 2300 Turnhout.
What is the equity of Ergotrics?
At the close of the 2025 financial year, the equity of Ergotrics amounts to -325,955 €, a solvency of -86.6% of total assets.
Who manages Ergotrics?
The register lists 5 active mandates at Ergotrics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Ergotrics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →